Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-10 · accession 0000899243-22-035782 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-11-14 | 2022-11-10+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $15.32 | -4,436 | 4,907 | -47% | -$68.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-10 | S | D | 4,413 | $15.32 | 4,930 | D | — | — | (F2) Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2022-11-14 | S | D | 23 | $15.04 | 4,907 | D | — | — |